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Plasma levels of neutrophil elastase-a^proteinase 
inhib i tor complexes and factor X I I I 
( including subunits A & S) i n septicemia and leucemia 
M. ]ochum \ K.-H. Duswald2, E. Hiller2, and H. Fritz1 
Introduction 
D u r i n g the i n f l a m m a t o r y response various or local tissue cells are 
activated thereby releasing internal , most ly lysosomal enzymes. 
D u e to the l iberat ion of these enzymes deplet ion of c lo t t ing factors 
i n septicemia or acute leucemia may occur via t w o major routes ( f ig . 
1): 
- System-specific proteinases, such as thrombokinases and 
plasminogen activators, trigger the activation of the c l o t t i n g , 
Endotoxins: cell membrane damage - proteinase liberation 
Thrombokinase 
Plasm in activator 
Specific activation 
of blood systems 
ο clotting 
ο fibrinolysis (FDP t) ^-J^asPi 
ο complement (C3at) 
ο kallikrein (kinin t) 
cells: platelets, phago­
cytes, mast cells 
»C1 INA 
- Granulocytic elastase; 
,,^^-cathepsins G; B, H, L; D 
αιΡΙ 
C12M 
aiAC 
ßiCI 
Inhibition 
Unspecific degradation 
ο blood system factors 
ο proteinase inhibitors 
ο transport proteins 
ο immunoglobulins 
ο tissue substances etc. 
phagocyte/lymphocyte 
activation 
Elimination of enzyme-inhibitor complexes by RES 
F i g . 1. C o n s u m p t i o n of plasma factors during inflammation. F o r details see text. 
Abbreviat ions: A n t i t h r o m b i n I I I ( A T I I I ) , a 2 - p l a s m i n inhibitor ( a 2 P I ) » C I activator 
( C I I N A ) , α ι - p r o t e i n a s e inhibitor ( c ^ P I , formerly α ^ a n t i t r y p s i n ) , 
« 2 - m a c r o g l o b u l i n ( a 2 M ) , a j - a n t i c h y m o t r y p s i n ( a 1 A C ) , ßa-collagenase inhibitor 
{ß\C\)> fibrin(-ogen) degradation products ( F D P ) , complement factor ( C 3 a ) , 
reticuloendothelial system ( R E S ) . 
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f ibr inolys i s , and complement cascades (summarized as »blood 
Systems«) b y substrate-specific proteolysis o f proenzymes or 
cofactors. D u e to the subsequent i n h i b i t i o n and rapid e l iminat ion 
of the e n z y m e / i n h i b i t o r complexes via the ret iculoendothel ial 
system (RES) n o t o n l y the proteinases b u t also their specific 
inhib i tors (e. g. a n t i t h r o m b i n I I I , a 2 - a n t i p l a s m i n , 
C I - inact ivator) are consumed. F o r a l o n g t ime the given sequence 
of reactions was assumed to be exclusiveley responsible f o r the 
development of disseminated intravascular coagulat ion. 
- Results obtained recent ly 1 ' 2 ' 3 ' 4 indicate that an addit ional 
reaction pathway contributes considerably to the consumpt ion of 
plasma factors d u r i n g severe in f lammat ions . This implies 
inact ivat ion of plasma proteins b y substrate-unspecific 
proteolysis due to l iberated lysosomal proteinases such as elastase 
and cathepsin G f r o m p o l y m o r p h o n u c l e a r granulocytes 
(neutrophils) . 
Especially elastase may destroy b l o o d proteins before i n h i b i t i o n 
occurs b y the plasma proteinase i n h i b i t o r s , αι-proteinase i n h i b i t o r 
( α α Ρ Ι , f o r m e r l y α χ -antitrypsin) a n d a 2 - m a c r o g l o b u l i n . O n account 
of these potent i n h i b i t o r s , direct measurement of the granulocyt ic 
proteinase activities i n plasma is n o t possible. H o w e v e r , increased 
levels of the elastase-α! P I complex ( E - a a P I ) w o u l d be an indirect 
but clear indica t ion of elastase l ibera t ion . Indeed Egbr ing and 
coworkers have demonstrated such complexes b y means of one-
and two-d imens iona l Laurel l electrophoresis i n plasma of patients 
suffering f r o m acute leucemia or septicemia 1 . 
I n the studies p e r f o r m e d i n our laboratory w e were especially 
interested to see whether a relationship exists between the levels of 
Ε -ο^ΡΙ complex and the severity of postoperative infections after 
major abdominal surgery, or c lo t t ing factor depletions i n acute 
leucemia. 
T o achieve this purpose, besides other factors, the levels of factor 
X I I I (measured b y a m o d i f i e d F XHI-Schnel l tes t f r o m 
Behringwerke M a r b u r g and b y rocket- immunoelectrophoresis ) 
and a n t i t h r o m b i n I I I (determined b y the coatest a n t i t h r o m b i n f r o m 
Deutsche K a b i , München) were cont inously m o n i t o r e d , because 
b o t h c lo t t ing factors are k n o w n to be easily degraded b y n e u t r o p h i l 
elastase i n v i t r o 5 , 6 . 
Quant i ta t ive estimation of the plasma levels of the 
elastase-α ^proteinase i n h i b i t o r complex was carried out w i t h a 
highly sensitive enzyme-linked immunoassay. This assay has been 
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developed recently by N e u m a n n and coworkers 7 and was adapted 
to cl inical condit ions i n our laboratory. 
B r i e f l y , the Ε-αχΡΙ complex i n the plasma sample is b o u n d to 
surface-fixed antibodies directed against neutrophi l elastase. A f t e r 
washing w i t h buffer , a second alkaline phosphatase-labelled 
ant ibody directed against α α Ρ Ι is f ixed to the complex. U n d e r 
suitable condi t ions , the activity of the b o u n d alkaline phosphatase 
F XIII (mean ± S.E.M) 
before op. course 
after op. 
during 
sepsis 
F i g . 2. Plasma levels of elastase-α r p r o t e i n a s e inhibitor complex ( Ε - ο ^ Ρ Ι ) and 
fibrin stabilizing activity of factor X I I I (F X I I I ) in patients subjected to major 
abdominal surgery. 
A = patients (n = 11) being without postoperative infection 
Β = patients (n = 14) surviving postoperative septicemia 
C = patients (n = 16) dying as a result of septicemia. 
T h e E-c t tPI levels are given as mean values ( ± S E M ) for the day before operation, the 
day after operation as well as for the postoperative phase before sepsis, at onset of 
sepsis and during septicemia. Last determinations were done on day of discharge ( D ) 
for group A , on day of recovery ( R ) for group B , and before death ( + ) for group C . 
nr = normal range 
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towards p-n i t rophenylphosphate is p r o p o r t i o n a l to the 
concentration of the E-a-i.PI complex i n the sample. 
Results and Discussion 
a) Levels of elastase-a LPI complex and factor XIII in patients after 
major surgery 
I n the prospective clinical s t u d y 8 more than 120 patients were 
inc luded. T h i r t y of them f u l f i l l e d defined septic criteria d u r i n g the 
postoperative course. O f these patients fourteen survived the 
infect ion (group B ) , whereas sixteen died as a direct result of 
septicemia (group C ) . Eleven patients, being w i t h o u t infect ion after 
abdominal surgery, served as controls (group A ) . 
W i t h the enzyme- l inked immunoassay n o r m a l levels of complexed 
elastase were f o u n d between 40 and 150 n g / m l i n 153 healthy 
individuals (mean value: 86.5 ± 25.5 n g / m l ) . 
As s h o w n i n f i g . 2 , i n patients w i t h o u t preoperative infect ion 
(group A and B) , the operative trauma was f o l l o w e d by an increase 
of the Ε - α α Ρ Ι level up to 3 - f o l d of the n o r m a l value. Patients 
suffering f r o m preoperative infections showed already clearly 
elevated preoperative complexed elastase levels. Immedia te ly after 
surgery a slight decrease was observed, p r o b a b l y due to e l iminat ion 
of the infect ion focus. 
A t the beginning of septicemia a h i g h l y significant increase of the 
complexed elastase could be detected: up to 6 - f o l d i n group Β and 
up to 10-fold i n group C. Peak levels were f o u n d above 2.500 n g / m l 
i n b o t h groups. The E-o^PI levels of septic patients w h o recovered 
showed a clear tendency towards n o r m a l values. I n patients w i t h 
persisting septicemia, h igh levels of complexed elastase were 
measured u n t i l death. 
I n comparison to the E - a t P I changes t h r o u g h o u t the postoperative 
phase, the factor X I I I act ivi ty showed an inverse pat tern ( f ig . 2) . A 
decrease i n F X I I I act ivi ty far below the n o r m a l value could be 
observed i n all three groups d u r i n g the early postoperative course. 
A t onset o f sepsis no statistically significant difference, either w i t h i n 
the infected groups or between these groups and the c o n t r o l , could 
be demonstrated. H o w e v e r , t h r o u g h o u t the course of septicemia, 
the factor X I I I act ivi ty in plasma of patients w h o d i d not survive 
decreased further up to 2 8 % of the standard mean value. Last 
determinations showed a clear tendency towards n o r m a l i n patients 
of the c o n t r o l group and of the group overcoming the infec t ion . I n 
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group C patients the mean value was st i l l below 3 0 % of the n o r m 
concomitant ly to the h igh ly elevated levels of E - c ^ P I . 
These patients also had very l o w concentrations of b o t h : subunit A 
compris ing the active enzyme, and subunit S representing the 
carrier p r o t e i n (data n o t shown) . I n cont ro l patients, however , o n l y 
the F X I I I act ivi ty and subunit A exhibited l o w values d u r i n g the 
early postoperative phase, whereas subunit S was diminished 
unsigni f icant ly . 
Interest ingly , d u r i n g c lot t ing , o n l y subunit A is consumed but n o t 
subuni t S. Elastase, however, is able to degrade b o t h subunits to a 
similar degree as demonstrated clearly by Egbring and c o w o r k e r s 1 , 
a . These data and the results presented i n our clinical t r i a l suggest 
that in the patients suffering f r o m septicemia, unspecific proteo ly t i c 
degradation b y neutrophi l elastase and/or other lysosomal 
proteinases is involved to a significant degree i n the depletion of F 
X I I I . 
The changes of the most impor tant plasma factors after major 
surgery are summarized i n f i g . 3: Simultaneously to the rise of 
E -o^PI complex a marked decrease of a n t i t h r o m b i n I I I , factor X I I I 
and a 2 - m a c r o g l o b u l i n as w e l l as an increase of the acute phase 
reactant C-reactive prote in was measured d u r i n g sepsis. These 
plasma factors all normalized i n patients w h o overcame the 
Parameter Sepsis Survival N o n - s u r v i v a l 
E - a , PI c o m p l e x ft η ft 
A n t i t h r o m b i n I I I Η η U 
Factor X I I I U η Η 
Ct2 Μ concent. u η W 
α5 Μ activity w η-Ι w 
C-reactive protein f t η t 
E : Elastase: a 2 M: a 2 - M a c r o g l o b u l m 
F i g . 3. Correlat ion of the increase of elastase-α,-proteinase inhibitor complex 
( Ε - α , Ρ Ι ) and the decrease of antithrombin I I I ( A T I I I ) , factor X I I I (F X I I I ) and 
« 2 - m a c r o g l o b u l i n (a2M) as well as the increase of the C-reactive protein ( C R P ) in 
plasma of patients suffering from septicemia after major abdominal surgery, 
η = normal value 
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Patients Diagnosis 
L e u k o c y t e s 
(χ 10 3 /μ1) 
Ε - α ι Ρ Ι 
(ng /ml) 
F X I I I activity 
(% o f the n o r m ) 
A T I I I activity 
(% o f the norm) 
K h A M L 3.5 27 87.5 87 
R e A M L 4.0 66 62.5 98 
E c A M L 10.6 96 37.5 66 
S c h ö A M L 163.0 170 50.0 70 
H i A M L 4.1 640 62.5 83 
B o A M L 17.9 840 50.0 88 
H a A M L 140.0 1140 50.0 98 
W e A P L 1.6 1320 87.5 104 
S i A P L 52.0 1600 n. d. n. d. 
M e C M L 7.8 132 120 109 
B o C M L 174.0 336 75.0 109 
R i C M L 381.0 750 75.0 110 
A y C M L 76.0 1000 120 107 
H e A L L 32.0 30 37.5 85 
Sa A L L 35.0 64 25.0 70 
R i A L L 69.5 68 25.0 100 
S c h i A L L 36.0 76 37.5 105 
Table 1. Leucocyte counts and plasma levels of elastase-arproteinase inhibitor 
complex ( Ε - α ^ Ρ Ι ) , factor X I I I , and antithrombin I I I in patients w i t h acute 
myelogenous leucemia ( A M L ) , acute promyelocyt ic leucemia ( A P L ) , chronic 
myelogenous leucemia w i t h blastic transformation ( C M L ) , or acute lymphatic 
leucemia ( A L L ) , respectively. F o r details see text. 
infect ion disease, whereas they showed pathological values i n 
patients w i t h fatal outcome. W e take this as a clear indica t ion that 
especially n e u t r o p h i l proteinases contr ibute s ignif icantly to the 
in f lammatory response of the organism. 
b) Levels of elastase-axPI complex and factor XIII in acute 
leucemia 
I n our pre l iminary s tudy of elastase release t h r o u g h o u t leucemia 9 , 
seventeen patients suffering f r o m various kinds of leucemia were 
included (table I ) . 
Pr ior to chemotherapy, six o u t of nine patients w i t h acute 
myelogenous leucemia ( A M L ) had moderate to h i g h levels of 
E - a i P l (170-1.440 n g / m l ) , the highest levels being f o u n d i n the t w o 
patients w i t h acute p r o m y e l o c y t i c leucemia ( A P L ; up to 1.600 
n g / m l ) . This type of acute leucemia is f requent ly associated w i t h 
disseminated intravascular coagulation. Elevated E - o ^ P I levels 
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(130-1.000 n g / m l ) were also measured i n the plasma of f o u r patients 
suffering f r o m chronic myelogenous leucemia w i t h blastic 
t ransformat ion ( C M L ) . I n contrast, none of the f o u r patients w i t h 
acute lymphat i c leucemia ( A L L ) had increased levels of E - a i P I . 
A l t h o u g h the f i b r i n stabil izing act ivity of F X I I I was f requent ly 
reduced i n A M L patients no clear correlation could be f o u n d 
between the absolute amount of elevated levels of E-a a P I and the 
decrease i n F X I I I act iv i ty . 
Surpr is ingly , the A L L patients showed extremely l o w F X I I I 
act ivi ty al though their Ε-αχΡΙ levels were in the n o r m a l range. I n 
contrast, C M L patients w i t h blastic t ransformation and increased 
E-aJ?! levels showed normal or even elevated F X I I I ac t iv i ty . 
A d d i t i o n a l l y , i n contrast to Egbr ing and c o w o r k e r s 1 , no clear 
correlat ion between elevation of Ε - α α Ρ Ι complex and decrease of 
subuni t S could be demonstrated (data not s h o w n ) . 
The A T I I I act ivi ty was i n the n o r m a l range, except f o r three 
patients. Their l o w A T I I I level, however, was also n o t correlated to 
a h igh Ε-αχΡΙ concentration. 
These pre l iminary data suggest that the mechanism of F X I I I 
depletion i n acute leucemia seems to be not direct ly dependent o n 
elastase l iberat ion , and should be therefore, dif ferent f r o m that 
postulated for septicemia. U n f o r t u n a t e l y , there is no explanation 
f o r this discrepancy at the moment . 
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Discussion 
Rasche: 
Y o u t o l d us that elastase i n h i b i t o r complexes are elevated i n patients 
w i t h acute leucemia. I w o u l d be interested i n w h a t stage of acute 
leucemia has b l o o d samples been taken. I am especially interested i f 
y o u have some data of those patients, w h o had a d r u g induced bone 
m a r r o w depression. 
Jochum: 
U n f o r t u n a t e l y I cannot tell y o u something about the stage of acute 
leucemia, because we have received the samples f r o m D r . H i l l e r 
f r o m M u n i c h and there was n o t enough t ime to get some 
i n f o r m a t i o n about the disease. B u t we also had samples after 
chemotherapy i n acute myelocyt ic leucemia and the starting values 
of the complexes were very h i g h and they came d o w n to n o r m a l 
d u r i n g chemotherapy and also the factor X I I I act ivi ty came up to 
normal value at the end of the chemotherapy. 
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Rasche: 
I t h i n k the question seems very i m p o r t a n t to me, because what is 
w i t h the elastase-inhibitor complexes d u r i n g the phase of 
hypoplast ic bone marrow? 
Jochum: 
W e have i n the meantime only one patient after chemotherapy, so I 
cannot answer y o u r question suff ic ient ly . 
Discussant: 
Several of the last speakers have alluded to possible connect ion 
between raised levels of elastase and lower levels of factor X I I I . W e 
all k n o w that D I C and septicemia are very complex disease states 
and I do n o t really feel convinced that elastase is the o n l y factor 
responsible for the factor X I I I decline. 
Egbring: 
We d i d n o t say that i t is the o n l y reaction. I have, i n the f i rs t slide, 
showed that three mechanisms are responsible for degradation of 
patients w i t h septicemia, inc luding D I C , possibly inc luding 
hyper f ibr ino lys i s . A n d another p o i n t is that factor X I I I may be 
degraded by bacterial proteinases. That is a hypothesis , b u t we w i l l 
attempt to prove i t . 
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